Skip to main content
Clinical Trials/NCT01556919
NCT01556919
Completed
Not Applicable

Development of an Esophageal Monitoring Device for the Assessment of Esophageal Epithelium Integrity With Mucosal Impedance

Vanderbilt University1 site in 1 country429 target enrollmentMarch 2012
ConditionsGERDEsophagitis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
GERD
Sponsor
Vanderbilt University
Enrollment
429
Locations
1
Primary Endpoint
Mucosal Impedance Values
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The investigators are looking at a novel approach to measuring gastroesophageal reflux disease (GERD) damage and reducing the need for costly and less optimal testing presently used for diagnostic and treatment purposes. The investigators will be using three custom mucosal impedance (MI) catheters, each designed to measure at slightly different spacing on the esophagus.

Detailed Description

During routine esophagogastroduodenoscopy (EGD), consented study participants will have a series of three (3) custom mucosal impedance (MI) catheters with an axial array of sensors positioned along the mucosal wall to directly measure mucosal impedance at various intervals. Each catheter will be manually guided by the physician through the working channel of the endoscope until the sensored tip is visible through the scope camera. The physician will place the sensored rings directly on the mucosa along the lumen. To obtain evaluable data, the sensors must remain in contact with the mucosa at each point for 5 seconds after a stable impedance reading has been captured. This process will be repeated for each of the three prototype catheters in each consented patient in order to determine the optimal catheter/sensor design. The catheters will be attached to a channeled feed that will record measurements on a dedicated computer.

Registry
clinicaltrials.gov
Start Date
March 2012
End Date
July 23, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Michael Vaezi

Medical Director

Vanderbilt University

Eligibility Criteria

Inclusion Criteria

  • Patients who are undergoing standard of care EGD with or without BRAVO placement;
  • Have GERD symptoms and/or have endoscopic esophagitis

Exclusion Criteria

  • Use of acid suppressive therapy within last 10 days;
  • Known history of Barrett's esophagus, gastric surgery, alcoholism, significant motility condition

Outcomes

Primary Outcomes

Mucosal Impedance Values

Time Frame: Values will be obtained at conclusion of EGD, an expected average of 5 minutes

Consented study participants will have a series of three (3) custom mucosal impedance (MI) catheters with an axial array of sensors positioned along the mucosal wall to directly measure mucosal impedance at various intervals. The catheters will be attached to a channeled feed that will record measurements on a dedicated computer.

Study Sites (1)

Loading locations...

Similar Trials